An Analysis of the Relationship Between the Genetic Polymorphisms of Interleukin 12 Receptor Subunit Beta 1 and Crohn's Disease in Chinese Patients

Second Affiliated Hospital of Wenzhou Medical University

Status: Completed

Conditions: Crohn's Disease

Treatments: Biological: Ustekinumab (UST)

Study type: Observational

Funder types: Other

Identifiers

NCT07057856

SAHoWMU-CR2025-01-222

Details and patient eligibility

About

From January 2018 to May 2025, diagnosed CD patients and gender- and age-matched normal controls were collected from Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. Our study aimed to explore the associations of interleukin 12 receptor subunit beta 1 (IL-12RB1) gene polymorphisms with the risk and clinicopathological characteristics of Crohn's disease (CD), and to analyze the effects of IL-12RB1 gene variations on the clinical response of ustekinumab (UST) treatment in CD patients at week 8.

Full description

From January 2018 to May 2025, diagnosed CD patients and gender- and age-matched normal controls were collected from Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. Genotypes of IL-12RB1 were examined by multiplex polymerase chain reaction-ligase detection reaction technique. Unconditional logistic regression analysis was employed to analyze the distribution differences of IL-12RB1 gene polymorphisms between CD group and normal control group, as well as their influences on the clinicopathological characteristics and 8-week clinical response to UST treatment of CD patients.

Enrollment: 866 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• diagnosed CD based on comprehensive clinical, colonoscopy, histopathological, laboratory, and radiographic examination results

Exclusion criteria

• rheumatoid arthritis, systemic lupus erythematosus, intestinal tuberculosis, ischemic enteritis, radiation enteritis, tumors, etc.

Trial design

866 participants in 2 patient groups

CD patients

Description:

Some CD patients received UST treatment and the first sufficient dose of UST (6mg/kg) was administered intravenously.

Treatment:

Biological: Ustekinumab (UST)

normal control

Description:

no biological agents treatment